Rethinking Parkinson's disease: could dopamine reduction therapy have clinical utility?

• Published in: Journal of neurology 2024-08, Vol.271 (8), p.5687-5695
• Main Author: Sackner-Bernstein, Jonathan
• Format: Article
• Language: English
• Subjects: Animals; Antiparkinson Agents - pharmacology; Antiparkinson Agents - therapeutic use; Dopamine; Dopamine - metabolism; Dopamine Agents - administration & dosage; Dopamine Agents - pharmacology; Dopamine receptors; Humans; Levodopa; Levodopa - administration & dosage; Levodopa - pharmacology; Medicine; Medicine & Public Health; Movement disorders; Neostriatum; Neurodegenerative diseases; Neurological Update; Neurology; Neuroradiology; Neurosciences; Neurotoxicity; Parkinson Disease - drug therapy; Parkinson Disease - metabolism; Parkinson's disease
• ISSN: 0340-5354; 1432-1459; 1432-1459
• DOI: 10.1007/s00415-024-12526-7

Following reports of low striatal dopamine content in Parkinson’s disease, levodopa was shown to rapidly reverse hypokinesis, establishing the model of disease as one of dopamine deficiency. Dopaminergic therapy became standard of care, yet it failed to reverse the disease, suggesting the understanding of disease was incomplete. The literature suggests the potential for toxicity of dopamine and its metabolites, perhaps more relevant given the recent evidence for elevated cytosolic dopamine levels in the dopaminergic neurons of people with Parkinson’s. To understand the relevance of these data, multiple investigations are reviewed that tested dopamine reduction therapy as an alternative to dopaminergic agents. The data from use of an inhibitor of dopamine synthesis in experimental models suggest that such an approach could reverse disease pathology, which suggests that cytosolic dopamine excess is a primary driver of disease. These data support clinical investigation of dopamine reduction therapy for Parkinson’s disease. Doing so will determine whether these experimental models are predictive and this treatment strategy is worth pursuing further. If clinical data are positive, it could warrant reconsideration of our disease model and treatment strategies, including a shift from dopaminergic to dopamine reduction treatment of the disease.